{"id":8399,"date":"2025-01-13T09:03:19","date_gmt":"2025-01-13T09:03:19","guid":{"rendered":"https:\/\/www.library.sath.nhs.uk\/research\/?p=8399"},"modified":"2025-06-20T08:42:34","modified_gmt":"2025-06-20T07:42:34","slug":"vest-the-uk-vedolizumab-real-life-experience-study-in-inflammatory-bowel-disease-2024","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2025\/01\/13\/vest-the-uk-vedolizumab-real-life-experience-study-in-inflammatory-bowel-disease-2024\/","title":{"rendered":"VEST: The UK vedolizumab real life experience study in Inflammatory Bowel Disease (2024)"},"content":{"rendered":"\n<p><strong>Type of publication:<\/strong><\/p>\n\n\n\n<p>Conference abstract<\/p>\n\n\n\n<p><strong>Author(s):<\/strong><\/p>\n\n\n\n<p>Bodger K.; Booker C.; Kok K.; Lobo A.; Ahmad T.; Bloom S.; *Butterworth J.; Irving P.; Cummings F.<\/p>\n\n\n\n<p><strong>Citation:<\/strong><\/p>\n\n\n\n<p>Journal of Crohn's and Colitis. Conference: 19th Congress of the European Crohn's and Colitis Organisation, ECCO 2024. Stockholm Sweden. 18(Supplement 1) (pp i1775-i1777), 2024. Date of Publication: January 2024.<\/p>\n\n\n\n<p><strong>Abstract:<\/strong><\/p>\n\n\n\n<p>Background: The characteristics and outcomes of patients treated with vedolizumab in routine healthcare settings have not been widely evaluated in the UK. Method(s): Prospective, multicentre observational study of 364 patients started on vedolizumab in UK practice from January 2017 until February 2019 using the UK IBD Registry clinical web-based tool. For the present analysis, the primary outcome was drug survival (persistence) at 1-year, defined as attendance for infusion &gt;=48 weeks after the first dose. Secondary outcomes were: Clinical remission (CR, based on partial Mayo score [&lt;=1] or Harvey Bradshaw index [&lt;=4]), physician global assessment (PGA), IBD-Control Questionnaire (IBD-Control-8, IBD-Control-VAS and individual item scores), laboratory parameters and adverse events. Result(s): Age (mean): 44 yrs; Males: 48%; IBD duration (mean): 6 yrs; Prev. resection: 18%; Steroids at baseline: 39%; Outcomes are summarized in Table 1. 37% of CD patients were assessed as being in clinical remission at baseline. Overall, 210 (58%) continued treatment beyond 48 weeks. At 1 year, 67.1% and 52.3% of CD and UC patients were in clinical remission with a clear improvement in QoL as assessed by IBD-Control -8. There were significant improvements across each IBD-Control-8 domain, including fatigue, with few patients considering switching treatment at that point (Figure 1). Conclusion(s): Vedolizumab was effective in clinical practice with 58% of patients remaining on treatment at one-year. Baseline status differed significantly from those recruited into RCTs. Patient reported outcomes demonstrated significant and meaningful improvements across physical, psychological, social and treatment domains.<\/p>\n\n\n\n<p><a href=\"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/Supplement_1\/i1775\/7587181\" target=\"_blank\" rel=\"noreferrer noopener\">Link to full-text<\/a> [no password required]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Conference abstract Author(s): Bodger K.; Booker C.; Kok K.; Lobo A.; Ahmad T.; Bloom S.; *Butterworth J.; Irving P.; Cummings F. Citation: Journal of Crohn's and Colitis. Conference: 19th Congress of the European Crohn's and Colitis Organisation,<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2025\/01\/13\/vest-the-uk-vedolizumab-real-life-experience-study-in-inflammatory-bowel-disease-2024\/\">Read more <span class=\"screen-reader-text\">VEST: The UK vedolizumab real life experience study in Inflammatory Bowel Disease (2024)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[1050,1003,221,981],"class_list":["post-8399","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-1050","tag-bronze-open-access","tag-gastroenterology","tag-inflammatory-bowel-disease"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/8399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=8399"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/8399\/revisions"}],"predecessor-version":[{"id":8735,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/8399\/revisions\/8735"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=8399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=8399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=8399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}